Wockhardt bags CDSCO's approval for export of up to 100 million doses of Sputnik Vaccines

8 Feb 2022 , 09:39 AM

Wockhardt Limited, a global Pharmaceutical and Biotechnology Company headquartered in India, on Tuesday announced that the company has received permission from the Central Drugs Standard Control Organization (CDSCO) enabling it to export up to 80 million doses of Sputnik Light and up to 20 million doses of Sputnik V Component I vaccine.

Drug inspectors from CDSCO (West zone) & Aurangabad State FDA and Expert from CDL Kasauli duly inspected Wockhardt’s Bulk vaccine and Fill-Finish manufacturing facilities at Waluj and Shendra, Aurangabad respectively, and approved it further to receive provide NOC.

Wockhardt has entered into an agreement with the Russian Direct Investment Fund and Enso Healthcare to manufacture and supply Sputnik V and Sputnik Light vaccines against COVID-19 on the back of technology transfer from Gamaleya National Research Institute of Epidemiology and Microbiology.

Wockhardt operated an automated manufacturing facility in Aurangabad which is entirely dedicated to producing world-class high-quality injectable products.

Wockhardt is research-based Global Biotech and Pharmaceutical Company. Wockhardt’s New Drug Discovery program has focussed on the development of Anti-bacterial drugs which can cure the spread of untreatable superbugs.

Wockhardt is currently trading at Rs401 up by Rs12.95 or 3.34% from its previous closing of Rs388.05 on the BSE. The scrip opened at Rs402.25 and has touched day’s high and low of Rs408.10 and Rs398 respectively.